- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01390753
Role of Human Milk Bank in the Protection of Severe Respiratory Disease in Very Low Birth Weight Premature Infants
Preventing Respiratory Disease Hospitalizations in Premature Infants Fed Donor Human Milk
Acute respiratory infections are the leading cause of hospitalization in premature infants worldwide. Severity rates are particularly high in developing countries. Numerous viruses can cause severe disease, but the most frequent agent of hospitalization is respiratory syncytial virus (RSV). In a recent study in Argentina, 58% of RSV infected VLBW infants required hospitalization and 19% required mechanical ventilation. One every twenty infected infants died. Unlike industrialized nations, VLBW infants in developing countries often lack access to prophylaxis against RSV with a commercially available monoclonal antibody (palivizumab). No vaccine or preventive intervention is available against any respiratory virus for infants younger than 6 months of age in developing countries and the public sector of most middle-income countries.
The protective role of breastfeeding against respiratory infections in developing countries is well established. But while similar beneficial effects have been described for premature infants, the dropout rate for breastfeeding in families exposed to the uncertainties and stress of the early months of life in the neonatal intensive care unit is very high. The World Health Organization recommends the use of Human Milk Donor Banks to feed infants that cannot be breastfed by their own mothers. These banks are established with the purpose of collecting, screening, processing (including pasteurizing), testing and distributing donated human milk. The potential benefit of donated milk against acute disease elicited by RSV is unknown. The investigators propose to study the role of supplemental donated human milk in the prevention of hospitalizations caused by RSV in non-breastfeeding premature infants. Since the investigators expect the benefits of breast milk to extend beyond protection against RSV, the effect of human milk against respiratory infections elicited by other viruses will also be evaluated.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, 1406
- Fundacion INFANT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- VLBW preterm neonates (birth weight <1,500 g at birth; gestational age <37 weeks) born alive at any of the two participating maternity hospitals integrating our network in Argentina will be enrolled in the study after signature of informed consent.
Exclusion Criteria:
- VLBW infants older than one month of age (e.g.: transferred from another institution), or formula fed for over ten days, or with congenital heart disease, congenital anomalies of the respiratory tract (i.e.: tracheoesophageal fistula, pulmonary hypoplasia, diaphragmatic hernia), immune suppression, severe malformations affecting breathing (i.e. anencephaly) as well as infants who die prior to completion of the first questionnaire, or living more than 40 km away from the Hospital will be excluded from participation. Infants born from human immunodeficiency virus (HIV) positive mothers will also be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Preterm formula
|
|
Active Comparator: Donor milk + preterm formula
Human milk from a donor bank
|
|
No Intervention: Breastfeeding + formula
|
|
No Intervention: Breasfeeding
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of respiratory episodes in premature infants
Time Frame: During the first year of life
|
During the first year of life
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Fernando P Polack, MD, Fundacion INFANT
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INFANT-001
- Donor milk study (Other Grant/Funding Number: Thrasher)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Infections
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusCanada
-
University of DerbySheffield Hallam University; University Hospitals of Derby and Burton NHS Foundation...CompletedRespiratory Muscle | Infections, Respiratory | Respiratory Physiology | Symptoms and General PathologyUnited Kingdom
-
University of Alabama at BirminghamRecruitingRespiratory Syncytial Virus InfectionsUnited States
-
University Hospital Southampton NHS Foundation...University College, London; Bill and Melinda Gates FoundationCompletedRespiratory InfectionsUnited Kingdom
-
University of EdinburghNHS LothianCompletedRespiratory InfectionsUnited Kingdom
-
PfizerRecruitingRespiratory Syncytial Virus InfectionsUnited States, Israel, Korea, Republic of, Japan, Canada
-
University Hospital, Strasbourg, FranceCompletedSARS (Severe Acute Respiratory Syndrome)France
-
Duke UniversityBiomedical Advanced Research and Development AuthorityEnrolling by invitationRespiratory Syncytial Virus Infections | COVID-19 Respiratory Infection | Influenza Viral Infections | Rhinoviral InfectionsUnited States
-
Meir Medical CenterBen-Gurion University of the Negev; Clalit Health ServicesUnknown
Clinical Trials on Human donor milk
-
Laura KairThe Gerber Foundation; Children's Miracle NetworkCompletedExclusive Breastfeeding | Breastfeeding Duration | Donor Milk SupplementationUnited States
-
Mount Sinai Hospital, CanadaMitacsRecruitingGestational Diabetes | Small for Gestational Age at Delivery | type1diabetes | Type2diabetesCanada
-
National and Kapodistrian University of AthensRecruiting
-
Tarah T ColaizyEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedNeurodevelopmental Outcomes of VLBW InfantsUnited States
-
University of ManitobaUniversity of CalgaryRecruitingPreterm Birth | Microbial ColonizationCanada
-
University of CalgaryUniversity of British Columbia; University of Victoria; NorthernStar Mothers...Not yet recruitingMicrobial ColonizationCanada
-
LactaLogics, IncRenown Regional Medical CenterCompleted
-
Children's Hospital of Fudan UniversityRecruiting
-
Neolac Inc dba Medolac LaboratoriesUniversity of LouisvilleCompletedNeonatal Abstinence SyndromeUnited States
-
National Center for Research Resources (NCRR)Baylor College of MedicineCompletedSepsis | Necrotizing EnterocolitisUnited States